Dr Ma on Sintilimab Plus Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Jun Ma, MD, discusses findings from the phase 3 CONTINUUM trial of sintilimab in combination with induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
Jun Ma Sun Yat Sen University Cancer Center Locoregionally Advanced Nasopharyngeal Continuum Trial Sintilimab In Combination With Induction Chemotherapy And Concurrent Chemoradiotherapy Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Source: onclive.com